Merck, Keytruda
Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback